Feedback / Questions
Polivy (polatuzumab vedotin-piiq) - Roche
Lunsumio (mosunetuzumab-axgb) - Roche
Polivy + Lunsumio: Regulatory approval in US for 2L+ DLBCL in 2026
(Roche)
-
Oct 12, 2025 -
Pharma Day 2025
FDA approval
•
Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology
https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf
Oct 12, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious